News | April 14, 2026
Briefs: Indoco Remedies and Panacea Biotec
Panacea Biotec receives LoA from CMSS
Panacea Biotec receives LoA from CMSS
Outlines 1,500-member internal cadre, digital regulatory system, and faster SEC-led reviews
Veteran biopharma leader stressed that generic medicines must be viewed separately from biologics
_256_384.jpg)
Effective recovery at home begins with well-defined care plans that outline treatment protocols, recovery milestones, and monitoring requirements tailored to individual patient needs
Benefits were consistent across all key subgroups, including patients previously treated with covalent BTK inhibitors
The new test offers a minimally invasive blood-based approach to tracking neurological damage, measuring neurofilament light chain
Highlights Mirvetuximab-based regimen promise
The campaign builds on the three-year partnership unveiled earlier this season
Spread across nearly 4,500 sq. ft., the new clinic combines advanced dental technology, experienced specialists, and an Atithi-first care model
The license is valid for five years, effective from April 9, 2026
Subscribe To Our Newsletter & Stay Updated
